Steve Harris, Non-Executive Chairman

Steve Harris.  Graduated with a Bachelors Degree in Pharmacy in 1964, and was admitted to membership of the Royal Pharmaceutical Society of Great Britain in 1965.  He was elected a Fellow of the Society in 2000. His entire career has been in the pharmaceutical industry working within multinational companies such as ICI Pharmaceutical Division (now Astra-Zeneca), Merck Sharp and Dohme, Eli Lilly and Reckitt and Colman, as well as start-up companies such as Gensia and Medeva.  He resigned as a Director of Medeva in 1995 to set up his own consultancy business.  Since then he has had a variety of non-executive directorships with biotechnology and pharmaceutical companies and has been involved in a number of IPO’s and fund raisings in addition to several business development consultancies.

Robert has 30 years experience in the natural products industry in the United States, Europe and China and was a major figure in the establishment of Chinese herbal medicine in the UK in the 1980s. He has broad experience in the areas of product development, manufacturing, quality control, and regulatory affairs relating to natural products. In 1997 he founded East West Biotech Limited, a company using proteomic technology for the development and quality control of botanical drugs which was acquired by Oxford Natural Products Limited (ONP) in 1999. Following the acquisition, he was responsible for business development at ONP until October 2000.  Robert co-founded Phynova in 2002.

Michael has been a partner in Anvil Partners (now Anvil Partners LLP) since 1995 where he specialises in raising finance for management buy-outs and development capital. He previously spent 18 years in investment banking in London, New York, Paris and Dublin with Kleinwort Benson and Allied Irish Investment Bank and qualified as an accountant with Price Waterhouse.

Hongwen Yu, Executive Vice President

Hongwen was a lecturer in the Department of Pharmacy, Shanghai University. She has worked for several companies which were developing medicines from plants. She is experienced in the development of plant-based medicines from "field to final dosage form". She has prepared the initial Chemistry, Manufacturing and Control (CMC) documents for submission to ethics committees and regulatory bodies for clinical trial approval and has successfully managed several development programmes from concept to products in clinical phase. As a Pharmacognosist, she is experienced in the authentication and quality assessment of natural products.

Ian Scoular PhD DMS, Director of Business Development

Ian has more than 20 years marketing and business development expertise in the pharmaceutical industry and experience in Rx, OTC and biotechnology. He has been responsible for identifying, assessing, structuring and negotiating many different types of commercial agreements. He led negotiations with AstraZeneca, resulting in the major licensing agreement with Protherics in December 2005. This deal was recognised at the 2006 Scrip Awards as 'Licensing Deal of the Year'. Ian started his industry career at Reckitt & Colman Pharmaceutical Division in Hull where both Phynova’s Chairman Steve Harris and Brian Whittle were colleagues.

Julie is ACCA qualifed as an Accountant. Previous to her position at Phynova, Julie led significant projects that brought about financial stability to a business that ultimately resulted in acquisition. Following this acquisition, Julie realigned financial systems and reporting with a FTSE100 group company. As Group Financial Controller & Company Secretary, she enjoys a broad ranging role within Phynova.

Shouming graduated from China Pharmaceutical University, Nanjing and received his PhD in Phytochemistry from Strathclyde University, Glasgow. He is currently the Guest Professor of Guizhou University, Visiting Professor of Guiyang Medical College and a Principal with CMM Consultant Associates (UK). Shouming was previously employed at ONP as the Director of New Product Development, mainly responsible for the research and development of products containing Chinese medicinal plant materials. Previously, he was the Director of Research & Development at East West Biotech Limited, overseeing and executing the development of a number of natural products.

Andrew graduated with an MSc from the University of Natal in South Africa in which he investigated the phytochemistry and biological activity of traditional South African medicinal plants. He has previously worked as a lecturer at the University of Natal, where he taught biochemistry and developmental biology, and for an international clinical research organisation in a business development role. In his current role, he oversees the company's research and development programme, where he is responsible for the management and co-ordination of all research and development projects.

Wendy has worked in the healthcare industry since 1981, with SmithKline & French, Glaxo Animal Health and Cyanamid of Great Britain. At Cyanamid she was Regulatory Affairs Manager for its subsidiaries and Business Development Manager for Lederle Laboratories (a subsidiary of Cyanamid). Her responsibilities included in-licensing and out-licensing, identifying potential new business areas, and monitoring and advising on strategic developments in areas which included antiinfectives and Oncology. During this period Cyanamid registered a number of new chemical entities, and novel delivery systems for established pharmaceuticals and innovative devices. In 1995 she established Subiaco Associates, which provides consultancy services to the healthcare industry.

Brian has over 40 years' experience in the pharmaceutical industry and was co-founder of Phytopharm and GW Pharmaceuticals plc

The board has established an audit committee and a remuneration committee both with formally delegated duties and responsibilites. The audit committee and the remuneration committee comprises of Steve Harris, as the Chairman, and Michael Martin. The nominations committee comprises of Steve Harris, as the Chairman, and Michael Martin.

The audit committee will receive and review reports from the Company's management and the Company's auditors relating to the annual and interim accounts and the accounting and internal control systems in use throughout the Group. The audit committee will have unrestricted access to the Group's auditors.

The remuneration committee will review the scale and structure of the Executive Directors' remuneration and the terms of their service contracts. The remuneration and terms and conditions of appointment of the Non-Executive Directors will be set by the Board. No Director may participate in any meeting at which discussion or decision regarding his own remuneration takes place. The remuneration committee will also administer any share option schemes and share incentive scheme.